Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05610891 · ClinicalTrials.gov registry record · Phase 1
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
A Phase 1 study of High Grade Glioma, sponsored by Cellectar Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 8
- Study locations
NCT05610891 is a Phase 1 study of High Grade Glioma that is active but no longer recruiting, run by Cellectar Biosciences. The registered enrollment target is 50 participants, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (23% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT05610891, a Phase 1 study of High Grade Glioma, is active but no longer recruiting, sponsored by Cellectar Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this dose finding study is to evaluate the safety and efficacy of 2 different dose levels of CLR 131 in children, adolescents and young adults with relapsed or refractory high-grade glioma (HGG).
Conditions Studied
Interventions
- DRUG CLR 131
Study Locations (8)
Texas
- UT Southwestern Medical Center - Dallas
- Texas Children's Cancer Center, Baylor College of Medicine - Houston
California
- Stanford University - Palo Alto
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Wisconsin
- University of Wisconsin, Carbone Cancer Center - Madison
Ontario
- Hospital for Sick Children - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05610891
The ClinicalTrials.gov registry entry for NCT05610891 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (23% lower). The listed sponsor is Cellectar Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High Grade Glioma appearing as the primary indexed condition, and to 1 intervention - of which CLR 131 is the first listed.
NCT05610891 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Texas, California, New York.
Frequently Asked Questions
What is clinical trial NCT05610891 about?
NCT05610891 is a clinical study titled "Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG". The purpose of this dose finding study is to evaluate the safety and efficacy of 2 different dose levels of CLR 131 in children, adolescents and young adults with relapsed or refractory high-grade glioma (HGG).
What is the current status of trial NCT05610891?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-10-01. Estimated completion is 2026-09.
What conditions does trial NCT05610891 study?
This clinical trial studies the following conditions: High Grade Glioma.
What interventions are being tested in trial NCT05610891?
The interventions under investigation include: CLR 131 (DRUG).
Who is sponsoring clinical trial NCT05610891?
This trial is sponsored by Cellectar Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05610891 being conducted?
This trial has 8 study locations across California, New York, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
RECRUITING · Phase 1
-
STARLITE for Unresectable High-Grade Gliomas
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
-
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
RECRUITING · Phase 1
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
-
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.